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Abstract: To determine the possible detrimental effects of multiple methotrexate 
doses has on the ovarian reserve and to determine the beneficial effects of 
dehydroepiandrosterone supplementation. The rats (n:24) divided into three groups; 
Group 1: control group, Group 2: dehydroepiandrosterone and methotrexate group 
(6mg/kg dehydroepiandrosterone dissolved in 0.1 ml sesame seed oil 
subcutaneously for ten days and 1mg/kg intramuscular methotrexate at the 1st, 3rd, 
5th and 7th days) and Group 3: methotrexate group (1mg/kg intramuscular 
methotrexate at the 1st, 3rd, 5th and 7th day). The groups compared in regards to 
their histopathological ovarian damage scores and AMH values. It established that 
multiple methotrexate applications had a considerable effect on reducing vascular 
congestion in the ovarian tissue. Both in groups 2 and 3 AMH values found to be 
significantly lower. When this decline in the ovarian reserve examined comparatively; 
while both the group 2 and 3 reported having a considerable and continuous 
reduction in the AMH levels correlative to the control group; the primordial, primary 
and total follicle counts shown to stay statistically the same in the group 2 
(p<0.0167). The dehydroepiandrosterone supplementation, while did not have a 
significant effect on reducing ovarian damage induced by methotrexate, also was not 
shown to provide any considerable increase in AMH levels. However, prolonged 
usage of dehydroepiandrosterone by contributing to the antral follicle pool 
considered promising in increasing the AMH levels conceivably. 
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INTRODUCTION 
Adjuvant chemotherapy is a widely applied medical treatment of gynecological 
malignancies. Chemotherapeutic agents have a toxic effect on gonads on varying 
degrees, and in turn, this is having a detrimental impact on ovarian reserve. The risk 
of ovarian insufficiency directly correlated with the mechanism of action of the agent 
used. The cumulative dosage, the duration of the treatment, and the age of the 
patients during treatment. It should note that with the younger patients, ovarian 
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reserves are in a considerably better state comparative to the patients over 40 years 
old. Lately, the effect of chemotherapy on the reproduction capacities and particularly 
the ovarian reserves have become even more debatable; because the number of 
patients who survives hematological malignancies and breast cancer has increased 
(Howell & Shalet, 1998). 
Another area where a chemotherapeutic agent such as Methotrexate is widely 
applied, besides the malignancies, is ectopic pregnancies (EP) (Lipscomb, 2007). EP 
is a significant condition that carries high morbidity and mortality rates, and 
depending upon the method of treatment may impact the future fertility potential of 
the patient. The decline in fertility due to loss of ovarian reserve. Resulting from; the 
condition itself (tubular rupture), the surgical treatment, the medical treatments 
utilizing Methotrexate, is a circumstance that needs further deliberation nowadays. 
The irreversible loss of the oocytes due to chemotherapy has brought upon 
new approaches to better conserve the fertility in these patients. Currently, the 
options on preserving fertility are the cryopreservation of oocyte and ovarian tissue 
and the freezing of embryo (Wallace, 2011). On a young patient with a healthy 
ovarian reserve, cryopreservation of oocyte may impact the future fertility of the 
patient positively. However, the main problem is with cases that receive 
chemotherapy before the cryopreservation of oocyte or ovarian tissue and with the 
facts that have insufficient ovarian reserves before treatment. In 2000, Casson and 
colleagues were the first groups to suggest DHEA supplementation to increase 
ovarian response in women with diminished ovarian reserves (DOR)(Casson, 2000). 
As a precursor of estradiol (E2) and testosterone, DHEA originates from the zona 
reticularis layer of the adrenal cortex and the theca cells of the ovary (Burger, 2002; 
Luchetti et al., 2004; Millier, Whitelaw, & Smyth, 1994). It conceived that for healthy 
follicular development and fertility, both estrogen and androgen are necessary. 
Casson and colleagues reported that the method of action for DHEA in oral 
supplementation on the follicular development and the oocyte quality is by increasing 
the insulin-like growth factor-I serum concentrations. 
The impact of DHEA on the ovaries with the patient group that receives 
Methotrexate never evaluated. The purpose of this study is to determine, primarily 
the ovarian damage induced by the Methotrexate in this group of patients with a 
strong desire of fertility and thus evaluating the ovarian reserves and subsequently to 
determine if DHEA offers any protective properties (preventive and reversing effects) 
against the detrimental impacts of Methotrexate. 
 
MATERIALS AND METHOD 
 This study conducted in the animal testing lab of the Üsküdar University, 
Istanbul, between the dates of March 25 and April 4 of 2019. The approval for this 
stud obtained from the Local Ethics Board for Animal Testings of Üsküdar University, 
İstanbul, Turkey. In this study, 24, 3-6 months old, 200-300gr, Norveginus species 
Sprague Dawley strain female rats used. The subjects were chosen at random and 
studied under three groups. Group 1: is the control group (n:8). On the first day of 
the study, intracardiac blood withdraws from the subjects residing in this group, and 
the ovaries of the rats were excised the same day with laparotomy and sent to 
pathology for a histopathological assessment. Group 2: is the DHEA + MTX group 
(n:8), and 1 mg/kg of methotrexate was applied intramuscularly at the 1st, 3rd, 5th, 
and 7th days of the study. The rats residing in this group received, as a 
supplementation, 6 mg/kg/day DHEA (dissolved in 0,1 ml sesame seed oil) 
subcutaneously for ten days. One of the subjects expired on day 6. Group 3: is the 
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MTX group (n:8), and the rats residing in this group received 1 mg/kg methotrexate 
intramuscularly at the 1st, 3rd, 5th, and 7th days of the study. On the 11th day, 2 ml 
of blood withdrawn from Group 2 and Group 3 for the assessment of AMH levels, 
and on the same day, their ovaries were excised and sent to pathology for a 
histopathological examination. 
 The medicines stored at + 4 C in a refrigerator. The rats were caged 
individually in a controlled environment (room temperature at 21 C and humidity at 
60%) with 12h light/dark cycles, and they fed ad libitum. As anesthetic during the 
excision of the ovaries with laparotomy, 10% ketamine hydrochloride at 80 mg/kg 
(Ketalar; Eczacıbaşı, Warner-Lambert, Istanbul, Turkey) and 2% xylazine 
hydrochloride at 15 mg/kg (Rompun; Bayer Health Care LCC, Kansas, KS) applied. 
The ovaries stabilized in a 10% formalin solution for pathological assessment after 
the excision. Before the AMH evaluation, the blood samples stored at -20 C. after the 
completion of the procedure, the animals were decapitated and disposed of using 
red medical waste bins. 
 After the administration of the drugs; primordial, primary, secondary, tertiary, 
atresia and total follicle counts, histopathological damage scores (follicular cell 
degeneration, vascular congestion, hemorrhage, edema, inflammation, and overall 
damage) and AMH values of the control group compared to the similar indicators 
from the other two groups. 
Mode of administration for MTX: 
 As advised by the US Bone, Reproductive and Urologic Drugs Advisory 
Committee (formerly Reproductive Health Drugs Advisory Committee), administered 
intramuscularly at the 1st, 3rd, 5th and 7th day (Emthexates ® 50 mg/2 ml flacon, 
Med-İlaç, Istanbul, Turkey). 
Mode of preparation and administration for DHEA: 
 DHEA (CAYMAN®, Dehydroepiandrosterone %97 1gr, Farmasina, Istanbul, 
Turkey), prepared by dissolving in sesame seed oil (0.01 ml dissolved in 95% 
ethanol, mixed with 0.09 ml sesame seed oil) (7). 
Histopathological assessments: 
 All pathology evaluationsents performed by the same specialist at the 
Pathology Clinic of Medical Sciences University, Kartal Education and Research 
Hospital, İstanbul, Turkey. Paraffin blocking was performed 24 hours after the 
oophorectomy, and afterward, 5-millimeter cross-sections obtained. Follicular activity 
evaluated by taking five random samples from each ovary. The samples were dyed 
with Hematoxylin + Eosin and then evaluated under a light microscope (Olympus 
BH2 Microscope, Olympus Corporation, Tokyo, Japan). These procedures were 
performed blindly by the same specialist. All follicles in the ovaries (primordial, 
primary, secondary, tertiary, and atresia) counted, and the ovarian reserves 
evaluated (Figure 1). Ovarian damage -including follicular cell degeneration, vascular 
congestion, hemorrhage, edema and inflammation (neutrophil infiltration) -was 
scored histologically using a graduated scale (0=none, 1=mild, 2=moderate, and 
3=severe) (Figure 1) 
. 
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Figure 1: The follicles in the ovaries and the ovarian damage A: Primordial (White 
arrowheads) and primary follicles (black arrowheads) (H&E, original magnification 
x400).B: Degenerate follicles and degenerate oocytes (White arrowheads) (H&E, 
original magnification x400). C: Primary (black arrowheads), secondary (White 
arrowheads), tertiary (White asterisk) follicles and atrophic follicles (White arrows) 
containing degenerated oocytes (Harrows, Original magnification x200) within a 
marked edema area (black asterisks).D: Edema (black asterisks), tertiary follicle 
(White asterisk), multiple congested vessels in between, (H&E, original magnification 
x200).E: Inflammatory cells within the ovarian stroma (area surrounded by White 
arrowheads) and crowded vascular structure (asterisk) (H&E, original magnification 
x400).F: Anthral follicle (asterisk) and primary follicles (White arrowheads) (H&E, 
original magnification x400). 
 
AMH measurement: 
 The blood was drawn through injection only at the end of the 1st day in the 
control group and at the end of the 11th day in the other groups intracardially during 
the operation after the ovaries excised. The blood samples placed in heparinized 
tubes (venotect®Italy). Blood was centrifuged in 30 minutes after it draws (15 
B A 
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minutes 1000×g). The serum removed, and the remaining plasma was placed in an 
Eppendorf tube and kept frozen at -20 °C until the day to be analyzed. AMH levels 
were measured from plasma in the form of “ng/ml” by a biochemist blind to the 
groups in University of Health Sciences, Dr. Lütfi Kırdar Kartal Training and 
Research Hospital, Department of Biochemistry, İstanbul/Turkey by using the ELISA 
(Gemini190605V2, Diatron MI Zrt, Hungary) method. All the samples tested in the 
same experiment. A kit with a sensitivity of.10 ng/mL, a detection range of 16–10 
ng/mL, and a variability coefficient of less than 10% used for the rat AMH kit 
(Elabscience, Rat AMH kit; Houston, Texas, ABD). 
Statistical analysis: 
 For the statistical analysis of the samples, IBM SPSS Statistics version 24 
utilized. Shapiro-Wilk and Kolmogorov Smirnov tests used to determine the normality 
of the samples. While, with the independent groups that conform with normal 
distribution, one-way variance analysis (ANOVA) utilized for the comparison between 
three or more groups; for the groups with deviations from the normal distribution, 
following the Kruskal-Wallis test for three or more comparison groups, the binary 
comparisons performed with Bonferroni adjusted Mann-Whitney test. After the 
Bonferroni correction, p <0.0167 was accepted to be statistically significant. Between 
the control group and the others, with the consideration of probable ovarian damage 
that will be caused by MTX, ROC curve analysis performed to establish an estimate 
for AMH level. The patients then divided into two groups based upon the estimate 
values found. Later, to determine the impact of total ovarian damage and subgroups 
and total follicle count and subgroups has on the AMH levels, and to establish the 
appropriate model binary logistic regression analysis performed. Correlation analysis 
performed to establish whether there was a linear relationship between the 
dependent variable AMH and the continuous variables. To determine if variations in 
the dependent variable were caused by the independent variables, with appropriate 
models and conditions, the Univariate Covariate Analysis of Variance (ANCOVA) 
test performed. A p-value of less than 0.05 considered statistically significant. 
  
RESULTS AND DISCUSSION 
 The groups studied under three subgroups as the control, the DHEA + MTX, 
and the MTX groups. The groups compared in regards to their ovarian reserve (OR) 
(follicle counts and AMH values) and ovarian damage scores (Table 1). In Group 2 
and Group 3, the decline of total follicle count and AMH values observed. However, 
the drop of the primordial, primary, and complete follicle counts and AMH values 
considered to be statistically significant (p<0.05). In regards to the reduction in the 
ovarian reserve, when studied in binary comparison; while the considerable decline 
in the AMH level continued both in the DHEA + MTX and the MTX groups 
comparative to the control group, it shown that the primordial, primary and total 
follicle counts have stayed statistically the same in the DHEA + MTX group 
(p<0.0167) (Table 2). 
 The data are presented in average± SD, or on average± Std. Error (*) or in n 
(%). For statistics, a: ANOVA, b: Kruskal Wallis Test, c: x2 test, and d: Univariate 
analysis used. *For corrected AMH values, the ANCOVA test was used (total 
damage =0.78 and atretic follicle =0.35). Ovarian damage —including follicular cell 
degeneration, vascular congestion, hemorrhage, edema and inflammation 
(neutrophil infiltration) —was scored histologically using a graduated scale (0= none, 
1= mild, 2= moderate, and 3= severe) 
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Table 1: Intergroup Comparisons of Follicle Counts, Ovarian Damage Scores 










Primordial follicle 5.75±3.88 1.86±2.27 1.50±0.93 .008b 
Primary follicle 11.75±6.36 6.00±5.13 4.38±2.97 .033b 
Secondary follicle 5.50±2.67 5.00±4.16 4.75±2.50 .454b 
Tertiary  follicle 9.38±4.21 6.71±1.60 4.63±4.60 .054b 
Atretic follicle 0.13±0.35 0.29±0.49 0.63±0.52 .112b 
Total follicle 32.38±13.16 19.57±10.18 15.25±11.95 .037b 
Hemorrhage 
0 8 (100) 7 (100) 8 (100) 
- 
1 0 0 0 
Vascular  
congestion 
0 3 (37.5) 5 (71.5) 8 (100) 
.025c 
1 5 (62.5) 2 (28.5) 0 
Cellular  
degeneration 
0 7 (87.5) 5 (71.5) 3 (37.5) 
.101c 
1 1 (12.5) 2 (28.5) 5 (62.5) 
Inflammatory 
cell infiltration 
0 8 (100) 7 (100) 8 (100) 
- 
1 0 0 0 
Edema 
0 5 (62.5) 7 (100) 8 (100) 
.039c 
1 3 (37.5) 0 0 
Total damage 1.13±0.99 0.57±0.56 0.63±0.52 .391b 
AMH (ng/ml) 2.73±0.52 0.08±0.02 0.09±0.03 .000a 
AMH (ng/ml)* 2.67±0.13 0.11±0.12 0.14±0.13 .000d 
The data are presented in average± SD, or in average± Std.Error (*) or in n (%). For 
statistics, a: ANOVA, b: Kruskal Wallis Test, c: x2 test and d: Univariate test were 
used. *For corrected AMH values, ANCOVA test was used (total damage =0.78 and 
atretic follicle =0.35). Ovarian damage —including follicular cell degeneration, 
vascular congestion, hemorrhage, edema and inflammation (neutrophil infiltration) —
was scored histologically using a graduated scale (0= none, 1= mild, 2= moderate, 
and 3= severe)  
   
 When the relationship between AMH and the follicles examined, it 
established that the best relationship formed with the primordial follicles. A significant 
positive correlation found between the AMH levels and the primordial follicle counts 
(correlation coefficient 0.54-0.55) (Figure 2). When the ROC curve performed to 
establish an estimated value between the control group and the other two in regards 
to the AMH and OR values, the expected point for the insufficient ovarian reserve 
was established at 1.06233 mg/ml for AMH. The sensitivity and the specificity of this 
value is 100% (area under the curve:1.000; p: .000) (Figure 3). If we were to 
acknowledge the control group as normal and assume the ovarian reserves decline 
in the remaining groups, it is an excellent test that exhibits insufficient ovarian 
reserve. It found that the was TPR (True Positive Rate) = one, and the was FPR 
(False Positive Rate) = 0. Thus, the test has a success rate of 100% in distinguishing 
between the diminished ovarian reserve and the normal ovarian reserve. 
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Table 2: Pairwise Intergroup Comparisons of AMH, Primordial, Primary 
and Total Follicle 
 
Groups and p 1–2 1–3 2–3 
p1 <.0001 <.0001 0,998 
p2 0,025 0,002 0,713 
p3 0,105 0,008 0,639 
p4 0,082 0,015 0,321 
P5 0 0 1 
1,2,3,4Mann-Whitney Test (p<.0.0167 was considered significant), 
5Univariate test. p1AMH, p2 primordial, p3 primary, p4 total follicle, p5 AMH 
corrected by using ANOVA. 
 
  
            
 
Figure 2: Correlation Between the AMH Levels and The Primordial Follicle Counts 
 
Under this estimation point, a binary group formed, one with diminished ovarian 
reserve (DOR) and the other with normal ovarian reserve, later, to establish the 
appropriate independent variables, binary logistic regression analysis performed. 
When the atresia follicle count and the total damage score models were examined 
collectively, in regards to their effects on the AMH level variations between groups, 
Nagelkerke R-square established at 0.643, and Cox & Snell R-square was set at 
0.466 and with the 82.6% rate the conjoint usage of these models found to be 
acceptable.  
 Covariance analysis reveals if there are any variations between the AMH 
values as the dependent variable amongst the groups. Furthermore, it also shows 
whether the differences in the dependent variable stems from the differences in the 
independent variables by subtracting the impact of the independent variables of the 
total score and the atresia follicle count. When these variables fixed at, the overall 
rating = 0.78 and the atresia follicle = 0.35, it revealed that the distinction, in regards 
to the AMH as the dependent variable amongst the groups, stayed the same and it 
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revealed to be p=0,000 between-group comparison. The variances amongst the 
groups were between groups 1 and 2 with 1 and 3. 
 
 
Figure 3: The Sensitivity and The Specificity of The Estimate Point for Insufficient 
Ovarian Reserve 
 
However, there were no distinctions between groups 2 and 3, and it established 
as p=1,000. The estimated AMH value, after the covariance analysis, was found as 
2.666 in group 1, 0.110 in group 2, and 0.137 in group 3. The total estimated AMH 
value found at 0.971. In conclusion, when the overall damage score and the atresia 
follicle count fixed, the variance of AMH values between the groups was continuous. 
Thus DHEA + MTX was found to be insufficient in enhancing the AMH levels and 
consequently, the ovarian reserve. 
Cancers are the primary condition that needs medical intervention and has the 
potential to impact upon reproductive functions during adolescence. Gonadotoxic 
treatments, ovarian surgery, premature ovarian insufficiency related to genetic and 
endocrine disorders are the conditions in which fertility needs to preserve. Evaluation 
of ovarian reserve is crucial in maintaining fertility in patients. Currently, AMH is the 
most commonly used marker while determining ovarian reserves. 
AMH is the marker secreted from granulosa cells of preantral and antral 
follicles, which can signal the early decline in the ovarian reserves (de Vet, Laven, de 
Jong, Themmen, & Fauser, 2002; Tremellen, Kolo, Gilmore, & Lekamge, 2005). 
AMH is also a useful marker in determining the effects of chemotherapeutic agents 
has on the ovarian reserves and in the follow-up after chemotherapy (Oriol et al., 
2008; Yeh, Kim, Liang, & Peresie, 2009). However, the most crucial marker for 
ovarian reserve is the histological assessment of the ovarian follicles (Oner, Ozcelik, 
Ozgun, & Ozturk, 2011). On the other hand, this is not a practical method, and even 
for research purposes, not always achievable in humans. Hence, the rat model was 
applied to investigate the effects of the medications on the ovarian reserve (Ozcelik 
et al., 2010). 
Very little known about the impact of MTX on ovarian reserve and the next IVF 
response of patients, It assumed that MTX is effecting fertility by targeting active 
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dividing granulosa cells in ovarian tissue. In return, it means a reduction in ovarian 
reserve or ovarian response. 
The use of adjuvant agents such as DHEA has become prevalent amongst the 
infertile patients despite the ambiguity about their effectiveness, and this brings 
controversy. To comprehend the effects DHEA has on ovarian follicles, the 
developmental process of follicles needs to established. As its known, with the 
multiplication of granulosa cells, primordial follicles develop into primary follicles, and 
primary follicles subsequently grow into preantral, antral, and Graafian follicles. The 
period needed for primordial follicles to develop into Graafian follicles in humans is 
three months. However, the primordial follicles that represent the ovarian reserves 
are inactive, and there are no markers that can use to estimate their numbers. 
Therefore, when speaking of ovarian reserve in clinical practice, instead of primordial 
follicle pool, it's about the developed antral follicles chosen from this pool (Monniaux 
et al., 2014). 
DHEA considered working by providing recovery from the atresia that effects 
preantral and small antral follicles that includes improvement in the FSH receptor 
expression and ovarian IGF-1 factor and additionally by inducing an increase in the 
antral follicle count (Artini et al., 2012; Casson et al., 1998). However, the 
effectiveness of DHEA supplementation on DOR is still controversial. 
In a study conducted by Bower and colleagues, the relationship between early 
menopause and the impact of chemotherapy targeting trophoblastic tumors studied, 
and it reported that usage of methotrexate as a sole agent resulted in menopause 
two years earlier when compared to patients not receiving chemotherapy (Bower et 
al., 1998). 
In a study performed by Şahin et al., systemic single-dose methotrexate 
treatment, salpingectomy followed by methotrexate, and salpingectomy alone were 
applied to ectopic pregnancy cases; AMH levels measured before and after surgery. 
AMH levels found to be reassuring, and surgical approaches reportedly did not have 
any detrimental effects on ovarian reserve (Sahin et al., 2016). Boots and his 
colleagues also concluded, in a study conducted on ectopic pregnancy cases, that a 
single dose application of MTX did not have any detrimental effects on the IVF 
results (Boots, Gustofson, & Feinberg, 2013). Oriol and colleagues reported that a 
single dose application of MTX treatment did not endanger ovarian reserve in terms 
of AMH levels (Oriol et al., 2008). However, in these studies, whether the MTX 
damages the developing follicles in the ovaries have not been uncovered. 
Furthermore, these studies conducted on patients who received lower doses of MTX 
and the effects of multiple MTX does not establish. 
Single-dose MTX application is the standard method in the medical treatment of 
EP. It mostly preferred on unruptured EP cases ("Medical treatment of ectopic 
pregnancy: A committee opinion," 2013). In the year 2014 Uluğ and Öner (Ulug & 
Oner, 2014) have researched the effects of single-dose and multiple-dose MTX 
applications with salpingectomy on the ovarian reserve; amongst the studied groups, 
single-dose use of MTX concluded to have the minimal negative impact on the 
ovarian reserve compared to the other groups; while the primordial follicle counts 
found comparable between the single-dose MTX group and the control group, they 
reported that total follicle counts and AMH levels declined significantly amongst 
every studied group. 
In the study conducted by Göl and colleagues with high doses of MTX on lab 
rats, it established that high doses of MTX caused damage on the primordial follicles 
in the ovaries of the rats. The authors reported that this finding could be significant in 
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regards to diminished reproductive performance and premature menopause in the 
following years after high dose MTX applications (Gol, Saygili, Koyuncuoglu, & Uslu, 
2009). 
We aimed to determine the probable damage caused by MTX on ovaries and 
ovarian reserves and also to establish the inhibitory effect of DHEA on these 
negative aspects as an androgen supplementation. In our study, we saw a significant 
reduction in the primordial follicle, primary follicle, and total follicle counts at the MTX 
group comparative to the control group. Once again, in the MTX group, AMH levels 
were found to be significantly lower compared to the control group. The distinction 
between our study and the studies done by Şahin, Boots, and Oriol and colleagues is 
that instead of a single dose application of MTX, in this study, multiple doses of MTX 
were applied. 
Similar to ours, in a study where instead of DHEA, alpha-lipoic acid utilized; it 
reported that in rats that received MTX, alpha-lipoic acid has reversed the AMH 
levels and the total follicle counts, and thus healing the oxidative damage to the 
ovaries. Karapınar and colleagues have concluded that the oxidative effects of MTX 
on the ovaries may be inhibited by alpha-lipoic acid supplementation which is an 
antioxidant (Soylu Karapinar, Pinar, Özcan, Özgür, & Dolapçıoğlu, 2017). 
We utilized DHEA instead of alpha-lipoic acid. In the studies conducted until 
now, DHEA only used in cases with suboptimal ovarian responses or diminished 
ovarian reserves. However, we applied DHEA supplementation to the rat model with 
ovarian damage, and diminished ovarian reserves induced my methotrexate. 
Nonetheless, the DHEA supplementation did not have any significant effects on 
restoring the AMH levels in the MTX + DHEA group. Additionally, when a binary 
comparison was made between all the groups, while the AMH levels were 
significantly lower in the MTX and the DHEA + MTX groups; primordial follicle, 
primary follicle, and total follicle counts were reduced considerably only in the MTX 
group (p<0.0167). 
The reason for DHEA supplementation not providing beneficial effects in our 
study may be due to the dosage and the timespan it administered. While the 
follicular recruitment period is three months for humans, it is two months for rats 
(McGee & Hsueh, 2000). As the primordial follicles were unaffected in this group, in 
regards to observing an increase in the AMH levels, extended use of DHEA found to 
be promising. Studies to this one show that primordial follicles may replace the 
follicles with developmental deterioration caused by short term MTX treatments for 
ectopic pregnancies. This phenomenon is explained with the higher resistance of the 
primordial follicles to ischemia because of their slower metabolic rate, compared to 
the follicle population in the developmental phase (Liu, Van der Elst, Van den 
Broecke, Dumortier, & Dhont, 2000; Nugent, Meirow, Brook, Aubard, & Gosden, 
1997).  
 Furthermore, we already comprehend that the effects of DHEA are relative to 
the dosage; as lower doses do not carry any increasing impact on the preantral and 
antral follicle counts, higher doses may increase the antral follicle counts however it 
also contributes to the miscarriages due to hyperandrogenism (Mahmoud, 
Mahmoud, Abo-Zeid, & Fares, 2018). In rats, DHEA metabolism may differ from 
humans. Albeit, the dosage of the medication was adjusted to meet with the serum 
blood level in the human model; however, the inability to measure the DHEA levels 
in the rat model is the constraint of our study. The lower case count of the groups is 
another constraint of this study. 
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CONCLUSION 
 This study demonstrated the toxic effect of MTX, the most widely applied 
chemotherapeutic agent for malign and benign gynecological disorders. This effect 
was achieved by multiple doses, while it established that the DHEA treatment was 
not preventing the ovarian damage caused by MTX, as the primordial follicles seem 
unaffected in the DHEA group, it offers hope in increasing AMH levels with 
prolonged usage. As the mechanism of action of DHEA based on folliculogenesis is 
substantially complicated. The need for randomized prospective studies designed 
with more full sample groups, various dosages, and different treatment periods is 
apparent to assess the protective effect of DHEA has on ovarian reserves. 
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